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Abstract
Drugs targeting the epidermal growth factor receptor (EGFR), such as cetuximab and panitumumab, have been
prescribed for metastatic colorectal cancer (CRC), but patients harboring KRAS mutations are insensitive to them and
do not have an alternative drug to overcome the problem. The levels of β-catenin, EGFR, and RAS, especially mutant
KRAS, are increased in CRC patient tissues due to mutations of adenomatous polyposis coli (APC), which occur in 90% of
human CRCs. The increases in these proteins by APC loss synergistically promote tumorigenesis. Therefore, we tested
KYA1797K, a recently identiﬁed small molecule that degrades both β-catenin and Ras via GSK3β activation, and its
capability to suppress the cetuximab resistance of KRAS-mutated CRC cells. KYA1797K suppressed the growth of tumor
xenografts induced by CRC cells as well as tumor organoids derived from CRC patients having both APC and KRAS
mutations. Lowering the levels of both β-catenin and RAS as well as EGFR via targeting the Wnt/β-catenin pathway is a
therapeutic strategy for controlling CRC and other types of cancer with aberrantly activated the Wnt/β-catenin and
EGFR-RAS pathways, including those with resistance to EGFR-targeting drugs attributed to KRAS mutations.
Introduction
The Wnt/β-catenin and RAS/extracellular signal-
regulated kinase (ERK) pathways play important roles in
the regulation of various cellular events, including pro-
liferation, differentiation, and transformation. Mutations
in genes in both pathways, such as adenomatous polyposis
coli (APC) and KRAS, which occur in as many as 90% and
in 40–50%1,2, respectively, of human colorectal cancers
(CRCs), are known to be involved in the initiation and
progression of CRC. Both APC and KRAS mutations
synergistically promote cellular transformation and tumor
growth3–5, which is attributed to the activation of the
RAS-ERK pathway via the aberrant activation of the Wnt/
β-catenin signaling caused the loss of APC6–8. One of the
key events in the crosstalk between the two pathways is
the stabilization of RAS, especially oncogenic mutant
KRAS, as well as β-catenin, caused by APC loss. RAS, as
well as β-catenin, is degraded via glycogen synthase kinase
3 beta (GSK3β)-mediated phosphorylation and sub-
sequent poly-ubiquitination-dependent proteasomal
degradation; however, the inactivation of GSK3β by the
loss of APC stabilizes these proteins9,10.
The epidermal growth factor receptor (EGFR), a tran-
scriptional target of the Wnt/β-catenin pathway11,12, is
also overexpressed in human CRC and plays a synergistic
role with the Wnt/β-catenin pathway in tumorigenesis13–
15. Therefore, therapies targeting both the Wnt/β-catenin
and EGFR-RAS-ERK pathways, especially those lowering
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the levels of β-catenin, RAS, and EGFR, can be ideal
approaches for the treatment of CRC. Based on the
identiﬁcation of the mechanism of RAS destabilization by
the Wnt/β-catenin signaling and the large increase in
both β-catenin and RAS levels in human CRC, we
screened and characterized small molecules that suppress
the growth of CRC cells via the destabilization of both β-
catenin and RAS16,17. KYA1797K, a small molecule
derived from the chemical synthesis of an initial hit,
directly interacts with the N-terminal regulator of G
protein signaling (RGS) domain of axin and results in the
phosphorylation and subsequent degradation of both β-
catenin and RAS via the activation of GSK3β16.
The drugs targeting the EGFR-RAS-ERK pathway, such
as the anti-EGFR antibody drugs including cetuximab and
panitumumab, have been prescribed as therapeutic drugs
for patients with cancers such as metastatic CRC. How-
ever, these drugs have limitations in their usage due to the
poor efﬁcacy or the insensitivity in patients harboring
KRAS mutations18–20, and have no alternative therapy.
Therefore, we tested the effects of KYA1797K on the
growth and transformation of KRAS-mutated CRC cells
resistant to cetuximab because KYA1797K reduces both
β-catenin and RAS protein levels. KYA1797K suppresses
the growth and transformation of CRC cells, reduces
tumor xenograft growth and decreases the colony for-
mation and growth of tumor organoids derived from CRC
patient tissues insensitive to cetuximab due to KRAS
mutations via the degradation of oncogenic KRAS and β-
catenin with EGFR repression.
Together, small molecules that degrade both β-
catenin and RAS via the transcriptional repression of
EGFR can be a potential therapy for the treatment of
CRC patients with aberrantly activated Wnt/β-catenin
and EGFR-RAS pathways attributed to the increase in β-
catenin, EGFR, and RAS as well as to their activation by
pathologically important APC, KRAS, and EGFR
mutations.
Materials and methods
Cell culture and reagents
Colorectal cancer (CRC) cells, including HCT15, RKO,
SW480, and DLD1, were purchased from the American
Type Culture Collection (ATCC, Manassas, VA, USA).
Isogenic human CRC cells, DLD-1 cells harboring wild-
type (WT), or mutant (MT) KRAS (D-WT and D-MT,
respectively)21 were provided by B. Vogelstein (John
Hopkins University School of Medicine, Baltimore, MD,
USA). DiFi cells were provided by Won-Ki Kang (Division
of Hematology-Oncology at Samsung Medical Center,
Seoul, Republic of Korea). All the cell lines were
authenticated using short tandem repeat proﬁling (Cos-
mogenetech, Seoul, Republic of Korea). RKO cells were
cultured in DMEM (Gibco Life Technologies, Grand
Island, NY, USA) supplemented with 10% fetal bovine
serum (FBS; Gibco Life Technologies). HCT15, DLD1,
SW480, DiFi, D-WT, and D-MT cells were maintained in
RPMI 1640 medium (Gibco Life Technologies) supple-
mented with 10% FBS. For the establishment of stable cell
lines, D-WT cells were transfected with Myc-KRAS-WT-
pcDNA3.1, Myc-KRAS-G12V-pcDNA3.1, or empty-
pcDNA3.1 plasmid, and were selected in a medium con-
taining G-418 (Sigma-Aldrich; St. Louis, MO, USA). For
the establishment of the APC knockout (KO) cell lines,
RKO cells were transfected with the LentiVRISPRv2
vector containing the APC gene guide sequence and were
selected in a medium containing puromycin (Sigma-
Aldrich, St. Louis, MO, USA). Lipofectamine (Invitrogen,
Waltham, MA, USA) and Lipofector-EZ (AptaBio,
Gyeonggi, Republic of Korea) were used for plasmid
transfection according to the manufacturer’s instructions.
KYA1797K was dissolved in dimethyl sulfoxide (DMSO)
(Sigma-Aldrich) for the in vitro studies. Cetuximab (C225,
Erbitux) was obtained from Merck (Darmstadt,
Germany).
Plasmids
The plasmids Myc-APC-pCMV were provided by Eric
R. Fearon (University of Michigan, USA). The constructs
Myc-WT-KRAS-pcDNA3.1 and Myc-G12V-KRAS-
pcDNA3.1 were previously generated9. To construct the
APC knockout vector using the CRISPR-CAS system, we
designed and synthesized the guide oligos targeting the
APC gene (upstream of the NGG PAM sequence) using
the following sequences: forward, 5′-
CACCGTCGCTCTTCATGGATTTTTA-3′; and reverse,
5′-AAACTAAAAATCCATGAAGAGCGAC-3′ (Bioneer,
Daejeon, Republic of Korea). Two oligos were annealed
and ligated into the BsmB1-digested lentiCRISPRv2 vec-
tor (Addgene, Cambridge, MA, USA), and transformed
into the JM109 bacterial strain. All the constructs and
mutations were conﬁrmed by nucleotide sequencing
analyses (Cosmogenetech, Daejeon, Republic of Korea).
Human CRC tissue microarray (TMA) analyses
The normal, polyp/adenoma, and adenocarcinoma
samples were analyzed using CRC TMA (Biomax, Inc.,
Rockville, MD, USA). Immunohistochemical analyses
were performed with anti-EGFR, anti-β-catenin, and
anti-pan-RAS antibodies. The TMA slides were visua-
lized by microscopy (Eclipse 80i; Nikon, Melville, NY,
USA). For quantitative analyses, the H-score of each
stained sample was determined by IHC proﬁler software
(Image J) using the following scale: H-score=3×,
highly positive population, +2×, positive population,
+1×, weak positive population, and +0×, negative
population.
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Animal study
All animal experiments were performed in accordance
with the Korean Food and Drug Administration guide-
lines. The protocols were reviewed and approved by the
Institutional Animal Care and Use Committee (IACUC)
of Yonsei University. C57BL/6J-Apcmin/+ (Apcmin/+) and
B6.129S-Krastm3tyj (KrasG12DLA2) mice were obtained from
the Jackson Laboratory. To generate Apcmin/+/KrasG12DLA2
mice for the tumor organoid experiment, Apcmin/+ mice
were crossed with KrasG12DLA2 mice. For the xenograft
study, athymic nu/nu mice were injected subcutaneously
in the dorsal ﬂank with D-MT (1 × 107 cells/mouse) in
200 µL of PBS: Matrigel® (1:1; BD Biosciences, San Jose,
CA, USA). When the mean tumor size was between
100–200 mm3, the mice were randomly divided into four
groups: vehicle, cetuximab, KYA1797K, or co-treatment
with KYA1797K and cetuximab. The tumors were mea-
sured using Vernier calipers every 3 days, and the volumes
were then calculated according to the following formula:
π/6 × length × width × height. Twenty-one days after the
drug treatment, the mice were killed, and the tumors were
excised and ﬁxed in 4% paraformaldehyde (PFA; Wako,
Richmond, VA, USA) or snap frozen in liquid nitrogen for
further analyses.
Tumor organoid experiments
For the human tumor organoid experiments, the use of
human tissue was reviewed and approved by the Institu-
tional Review Board of Severance Hospital, Yonsei Uni-
versity College of Medicine. The biopsied tumor samples
from CRC patients were cut into 3–5mm pieces, washed
with ice-cold PBS three times, and incubated with col-
lagenase II (2 mg/mL), hyaluronidase (20 µg/mL), and
Ly27632 (10 µM) for 1 h at 37 °C. Small intestinal tumors
from ApcMin/+/KrasG12DLA2 mice were isolated and
washed with ice-cold PBS, and single cells isolated from
the tumors were collected using 0.25% trypsin containing
10mM Ly27632 and 100 µg/mL Primocin™ for 30 min.
After incubation, 1 × B27 was added, and the mixture was
ﬁltered through 100 µm and 40 µm cell strainers (BD
Biosciences, San Jose, CA, USA) to collect single cells. The
cells were mixed with growth factor-reduced Matrigel®
(BD Bioscience). After the gel solidiﬁed, N2 medium
containing 10% R-spondin-1 CM, 100 µg/mL noggin, 1.25
mM N-acetyl cysteine, 10 mM nicotinamide, 50 ng/mL
EGF, 10 nM gastrin, 500 nM A83-01, 3 µM SB202190, and
10 nM prostaglandin E2 was added. The growth medium
was refreshed every 2 days, and the cells were passaged by
mechanical disruption every 10–14 days at a 1:5 split
ratio. The measurements of tumor organoid growth were
performed by a CellTiter-Glo® assay (Promega, Madison,
WI, USA) according to the manufacturer’s instructions.
Luminescence was measured using a FLUOstar Optima
instrument (BMG Labtech, Cary, NC, USA).
Immunoblotting
Immunoblot analysis was performed as previously
described16. Immunoblotting was performed with the
following antibodies: anti-pan-RAS (sc-4), anti-β-catenin
(sc-7199), anti-ERK (sc-514302), anti-APC (sc-896), anti-
PCNA (sc-56), anti-KRAS (sc-30), and anti-Myc (sc-40)
purchased from Santa Cruz Biotechnology; anti-p-ERK
(9101) and anti-α-tubulin (3873) obtained from Cell Sig-
naling Technology; and anti-EGFR (ab52894) and anti-p-
EGFR (ab5644) purchased from Abcam (Cambridge,
United Kingdom).
GTP-RAS pull-down assays
For the detection of GTP-RAS (active RAS), the GST-
Raf1 RAS-binding domain (RBD) fusion protein was
puriﬁed from cell lysates of transformed BL21 cells using
glutathione-agarose beads and then resuspended in GST-
FISH buffer [10% glycerol, 50 mM Tris (pH 7.4), 100mM
NaCl, 1% NP-40, and 2mM MgCl2] with a 50% bead
slurry. Puriﬁed GST-Raf1 RBD proteins were incubated
with the WCL of D-WT or D-MT cells treated under the
indicated conditions, and the beads were washed with
GST-FISH buffer at least ﬁve times. The pull-down
samples were subjected to immunoblot analyses.
Cell proliferation assays
For the cell proliferation assays, CRC cells were plated
at a density of 2–5 × 103 cells/well in a 96-well plate. The
cells were then treated under the indicated conditions for
96 h. After incubation, 3-(4,5-dimethylthiazol-2-yl)-2-5-
diphenyltetrazolium bromide (MTT; Amresco, Solon,
OH, USA) reagent was added to each well at a con-
centration of 0.25 mg/mL for 2 h at 37 °C. Insoluble pur-
ple formazan was obtained by removing the medium and
extracting it with DMSO. The absorbance at 590 nm was
monitored with the FLUOstar Optima microplate reader
(BMG Labtech).
Colony formation assays
CRC cells were seeded in 12-well plates (250–600 cells/
well). The cells were treated under the indicated condi-
tions for 7–16 days with changes of the medium every
4 days. At the end of the experiment, the cells were
washed, ﬁxed, and stained with 0.5% crystal violet in 20%
ethanol for 2 h, and subsequently washed three times with
distilled water.
Reverse transcription and quantitative real-time PCR
The total RNA was isolated using TRIzol® reagent
(Invitrogen, Waltham, MA, USA) according to the man-
ufacturer’s instructions. The total RNA (2 µg) was reverse
transcribed using 200 units of M-MLV reverse tran-
scriptase (Invitrogen) in a 20 µL reaction mixture at 42 °C
for 1 h. For quantitative real-time PCR analyses, the
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resulting cDNA (1 µL) was ampliﬁed in 10 µL of‘ Rotor-
gene SYBR® green (Qiagen, Hilden, Germany). The
comparative cycle threshold (CT) method was used, and
β-actin served as an endogenous control. The primers are
listed in the supplementary table S1.
Immunohistochemistry
Immunohistochemistry (IHC) was performed as pre-
viously described17. For peroxidase IHC analysis, sections
were incubated with the primary antibody overnight at 4 °
C, followed by incubation with biotinylated anti-mouse
(Vector Laboratories, Burlingame, CA, USA) or biotiny-
lated anti-rabbit (Vector Laboratories) secondary anti-
bodies at RT for 1 h. The samples were incubated in the
avidin-biotin complex solution (Vector Laboratories),
they were then stained with 3, 3′ diaminobenzidine (DAB;
Vector Laboratories) for 5 min and counterstained with
Mayer’s hematoxylin (Muto, Tokyo, Japan). The signals
were analyzed using a bright ﬁeld microscope (Nikon TE-
2000U). The ﬂuorescence signal was visualized using a
confocal microscope (LSM510; Carl Zeiss, Oberkochen,
Germany) at excitation wavelengths of 488 nm (Alexa
Fluor® 488), 543 nm (Alexa Fluor® 555), and 405 nm
(DAPI). At least three ﬁelds of view per section were
analyzed. The IHC images were quantiﬁed from the
representing images using an IHC proﬁler in the ImageJ
software.
Immunocytochemistry
Cells were seeded on collagen-coated (500 µg/mL)
coverslips. The cells were then ﬁxed with 5% formalin for
30min, permeabilized with 0.1% Triton X-100 for 20min,
and preblocked with PBS containing 5% bovine serum
albumin (BSA; Affymetrix, Santa Clara, CA, USA) and 1%
normal goat serum (NGS; Vector Laboratories) for 1 h.
The cells were then incubated with the indicated primary
antibody overnight at 4 °C, followed by Alexa Fluor 488
(Life Technologies, Carlsbad, CA, USA) or Alexa Fluor
555 (Life Technologies) secondary antibodies for 4 h at 4 °
C and counterstained with DAPI for 10min at room
temperature. After incubation, the cells were mounted in
Gel/Mount media (Biomeda Corporation, Foster City,
CA, USA). The ﬂuorescence signal was visualized using a
confocal microscope (LSM510; Carl Zeiss) at excitation
wavelengths of 488 nm (Alexa Fluor® 488), 543 nm (Alexa
Fluor® 555), and 405 nm (DAPI).
Mutational analyses of human CRC patient samples
To analyze the mutational status of both APC (chr5,
NM_000038.5) and KRAS (chr12, NM_033360.3) in the
CRC patient samples, total genomic DNA was isolated
from the tumor organoids and analyzed by whole exome
sequencing (Macrogen).
Statistical analysis
All the data are represented as the means ± standard
deviations of at least three independent experiments. The
statistical signiﬁcance was assessed using the Student’s t-
test. The signiﬁcance was denoted as *P<0.05, **P<0.01,
and ***P<0.001.
Results
The levels of β-catenin, RAS, and EGFR are increased in CRC
patient tissues
Given that both β-catenin and RAS are stabilized in
CRC patient tissues mostly having APC mutations and
that EGFR is a transcriptional target of the Wnt/β-catenin
pathway, we tested whether expression levels of β-catenin,
RAS, and EGFR are correlated in CRC patient tissues. The
levels of the EGFR were higher along with β-catenin and
pan-RAS, especially in the polyp/adenoma and adeno-
carcinoma regions of the CRC patient tissues, compare
with paired normal tissues (Fig. 1a, b). Similar correlated
increases of the proteins were observed in APC- or
CTNNB1 (encoding β-catenin)-mutated CRC cell lines
(Fig. 1c). In addition, two independent CRC cohorts from
the oncomine database indicated that the mRNA level of
EGFR in the CRC tissues including adenoma, carcinoma,
or adenocarcinoma is higher than that in the normal
colon tissues (Supplementary Figure S1). These results are
correlated with the protein level pattern of EGFR in the
CRC patient tissue microarrays (TMAs). To further
conﬁrm these increases in the β-catenin, pan-RAS, and
EGFR levels by pathologically meaningful APC loss in
CRC, we generated RKO cells with the knockout (KO) of
APC. The levels of β-catenin, pan-RAS, and EGFR were
simultaneously increased (Fig. 1d), and the mRNA levels
of the EGFR and CCND1 (cyclin D1) genes, both well-
known Wnt/β-catenin signaling response genes, were
increased in the APC-KO RKO cells (Fig. 1e). Further-
more, the growth and transforming abilities of the APC-
KO RKO cells were signiﬁcantly elevated compared with
those of the RKO cells (Fig. 1f, g). In addition, all of the
APC knockout effects were rescued by the overexpression
of APC in APC-KO RKO cells (Fig. 1h, i).
The Wnt/β-catenin pathway-dependent co-regulation
of EGFR and RAS was also conﬁrmed by the increased
levels of these proteins induced by recombinant Wnt3a
treatment in both HEK293 and RKO cells harboring wild-
type (WT) APC and CTNNB1 (Supplementary Fig-
ure S2a) and by the decreased levels of these proteins
induced by the knockdown of β-catenin in both HCT15
and DLD1 cells harboring APC mutations (Supplemen-
tary Figure S2b). The mRNA levels of EGFR and CCND1
were increased and decreased by Wnt3a treatment and β-
catenin knockdown, respectively (Supplementary Fig-
ure S2c and d). Therefore, EGFR and β-catenin/RAS are
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increased by the loss of APC in CRC cells at both the
transcriptional and protein levels.
The stabilization as well as the mutation of RAS
contributes to the cetuximab resistance of CRC cells
Although drugs targeting the EGFR, such as cetuximab,
have been used for the treatment of CRC, their efﬁcacies
were limited because the drugs were ineffective for the
treatment of patients having KRAS mutations18–20.
Similarly, the growth of KRAS-mutated D-MT, HCT15,
and SW480 cells was not signiﬁcantly inhibited, while the
growth of DiFi and D-WT cells harboring WT KRAS was
effectively inhibited by cetuximab (Fig. 2a).
The resistance to cetuximab in CRC cells with KRAS
mutations was further investigated by using D-WT cells, a
DLD-1-derived cell line that harbors only WT KRAS21.
Although 90% of the growth of D-WT cells was inhibited
by cetuximab treatment for 96 h, only 10% of the growth
Fig. 1 The levels of β-catenin, RAS, and EGFR are increased by APC mutations and correlate with the growth and transformation of CRC
cells. a Immunohistochemical (IHC) analysis of β-catenin, RAS, or EGFR in the CRC patient tissue microarrays (TMAs) containing normal, polyp/
adenoma, and adenocarcinoma. Scale bar, 50 µm. b The quantitative analyses of positive signals in the IHC images were performed by comparing
the H-scores of staining for β-catenin, RAS, or EGFR in normal tissues and at different stages of colorectal tumorigenesis. Normal mucosa (n= 10),
polyp/adenoma (n= 9), and adenocarcinoma (n= 15). c Immunoblot (IB) analysis to detect β-catenin, RAS, and EGFR in various CRC cell lines
harboring different mutations of APC or CTNNB1. d–g The effects of APC knockout (KO) on the expression of β-catenin, RAS or EGFR and on cell
growth/transformation. The APC-KO RKO cells and RKO cells expressing the control vector alone were grown, and IB analyses were performed with
whole cell lysates (WCLs) to detect each protein (d). Quantitative polymerase chain reaction (qPCR) assays were performed to determine the
expression of the EGFR and CCND1 mRNAs (e). 3-(4,5-Dimethylthiazol-2yl)-2-5-diphenyltetrazolium bromide (MTT) assays (f) were performed for
measurements of cell growth, and foci formation assays (g) were performed to detect cellular transformation. h, i The effects of overexpression of
APC. The APC-KO RKO cells were transfected with Myc-tagged APC for 36 h, and the WCLs were subjected to IB analysis (h). The relative cell growth
was measured by the MTT assay (i). The data are presented as the mean ± SD. Two-sided Student’s t-test, *P<0.05, **P<0.005, and ***P<0.001
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was inhibited in cells overexpressing MT (G12V)-KRAS
(Fig. 2b). Interestingly, cetuximab resistance was also
observed for the overexpression of WT KRAS, although
the degree of resistance was somewhat lower (65%)
(Fig. 2b). These results were similar to the inhibitory
patterns of cell proliferation measured by the bromo-
deoxyuridine (BrdU) incorporation assays (Fig. 2c, d). The
patterns of antiproliferation induced by KRAS over-
expression correlated with the ERK activity in the cells
treated with cetuximab (Fig. 2e). Overall, the resistance to
the EGFR inhibitor cetuximab affecting CRC cell growth
was due to the increase in the level as well as the mutation
of KRAS.
KYA1797K, a small molecule that degrades both β-catenin
and RAS, overcomes cetuximab resistance in CRC
Because the increase in β-catenin, RAS, and EGFR levels
in CRC contributes to synergistically promote cell growth
and transformation, we tested the effects of KYA1797K on
the growth of CRC cells, especially cells resistant to
cetuximab, due to KRAS mutations. KYA1797K dose-
dependently inhibited the growth of various CRC cells
regardless of their KRAS mutational status (Fig. 3a), while
the growth of CCD18-Co, normal colon cell, was mildly
affected by KYA1797K treatment (Supplementary
Figure S3). The effectiveness of KYA1797K but not
cetuximab on the inhibition of the growth and transfor-
mation of cells harboring KRAS mutations was conﬁrmed
by comparing WT- and MT-KRAS CRC cells (Fig. 3b, c;
Supplementary Figure S4a and b). Co-treatment with
cetuximab and KYA1797K cumulatively inhibited the
growth of D-WT cells but not D-MT cells (Fig. 3b). The
differential effects of co-treatment with KYA1797K and
cetuximab on the growth of CRC cells, which are
dependent upon the mutational status of KRAS, were also
observed in a dose-dependent manner in WT KRAS D-
WT and DiFi cells but not in the KRAS-mutated D-MT
and SW480 cells (Fig. 3d).
The inhibition of ERK activity, as well as GTP-RAS
activity, by treatment with cetuximab or KYA1797K alone
or in combination in CRC cells with different KRAS
mutations was correlated with cell growth and transfor-
mation (Fig. 3e and Supplementary Figure S4c). The levels
of β-catenin, RAS, and EGFR were reduced by KYA1797K
but not by cetuximab although the p-EGFR levels were
reduced by both cetuximab and KYA1797K treatment in
WT and MT KRAS cells. Consistently, the EGFR mRNA
levels were reduced without a change in the β-catenin
mRNA levels by KYA1797K but not by cetuximab alone
(Supplementary Figure S5). Overall, it was shown that
Fig. 2 The overexpression of WT KRAS, as well as the mutant form, contributes to the resistance to cetuximab. a MTT assays were performed
to determine the effects of cetuximab on the growth of various CRC cells treated with the indicated doses of cetuximab for 96 h. b–e The effects of
the overexpression of KRAS WT or oncogenic mutant G12V on cell growth. The D-WT cells stably expressing Myc-KRAS-WT, -G12V, or empty vector
were treated with 5 µg/mL cetuximab for 96 h. MTT (b) and bromodeoxyuridine (BrdU) incorporation (c, d) assays were performed to measure cell
proliferation. Scale bar, 100 µm. The WCLs were subjected to IB analyses (e). The data are presented as the mean ± SD (n= 3). Two-sided Student’s t-
test, *P<0.05, **P<0.005, and ***P<0.001
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KYA1797K degrades both β-catenin and RAS proteins
with the transcriptional repression of EGFR. Treatment
with KYA1797K overcame the ineffectiveness of cetux-
imab for inhibiting the colony formation ability and
growth of CRC cells harboring KRAS mutations.
KYA1797K overcomes the resistance to cetuximab
attributed to KRAS mutations in tumor xenografts
The effectiveness of KYA1797K in the cetuximab-
resistant CRC cells harboring KRAS mutations was also
tested in vivo using a xenograft mouse model that
Fig. 3 KYA1797K overcomes the resistance to cetuximab attributed to KRAS mutations on the growth and transformation of CRC cells. a
MTT assays were performed to determine the effects of KYA1797K on the growth of various CRC cells treated with the indicated doses of KYA1797K
for 96 h. b, c The D-WT or D-MT cells were treated with vehicle, 25 µM KYA1797K, 5 µg/mL cetuximab, or were co-treated with both for the indicated
time periods. The growth and transformation of the D-WT or D-MT cells were monitored by MTT (b) and foci formation (c) assays, respectively. d MTT
assays were performed to determine the combined effect of KYA1797K and cetuximab in D-WT, DiFi, D-MT, and SW480 cells co-treated with the
indicated doses of KYA1797K and cetuximab for 96 h. e IB analysis of D-WT or D-MT cells treated under the indicated conditions for 24 h. Glutathione-
S-transferase (GST)-Raf-1 RAS-binding domain (RBD) pull-down assays were performed to detect active RAS (GTP-RAS). The data are presented as the
mean ± SD (n= 3). Two-sided Student’s t-test, **P<0.005, and ***P<0.001. NS not signiﬁcant
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produced tumors after the implantation of D-MT cells
harboring both APC and KRAS mutations. Mice intra-
peritoneally (i.p.) injected with cetuximab did not show an
effect in tumor growth, whereas mice treated with
KYA1797K alone or co-treated with KYA1797K and
cetuximab showed a signiﬁcantly reduced tumor volume
and weight (Fig. 4a, b). In agreement with the results of
the in vitro studies, treatment with KYA1797K alone or in
combination with cetuximab but not cetuximab alone
reduced ERK activity and reduced β-catenin, RAS, EGFR,
and proliferating cell nuclear antigen (PCNA) protein
levels, as shown by the immunoblots (Fig. 4c), immuno-
histochemical analyses, and subsequent quantiﬁcation
(Fig. 4d, e). Together, these results indicate that
KYA1797K efﬁciently suppressed the growth of tumors
and overcame the insensitivity to cetuximab in the KRAS-
mutated cells via degradation of the KRAS protein.
KYA1797K suppresses the growth of cetuximab-resistant
tumor organoids derived from ApcMin/+/ KrasG12DLA2 mice
or CRC patients harboring mutant KRAS
To further validate the effectiveness of KYA1797K but
not cetuximab, we adapted a tumor organoid culture
system. Similar to the results of the tumor xenograft
studies, both the formation and growth of the tumor
organoids from the small intestine of ApcMin/+/KrasG12-
DLA2 mice having both Apc and Kras mutations were
speciﬁcally suppressed by KYA1797K (Fig. 5a, b).
Fig. 4 KYA1797K overcomes the resistance to cetuximab attributed to KRAS mutations on tumor xenograft growth. a D-MT cells were
subcutaneously injected into nude mice with the subsequent intraperitoneal (i.p.) injection of vehicle, 20 mg/kg KYA1797K, 1 mg/mouse cetuximab,
or a combination of KYA1797K (20 mg/kg) and cetuximab (1 mg/mouse) for 21 days. The tumor volumes were measured every 3 days. b The
measurement of tumor weights (b, upper panel) and the visualization of tumor images (b, lower panel) were performed at the time of killing. cWCLs
prepared from the tumor tissues were subjected to IB analysis. d IHC analysis of the tissue sections incubated with the indicated antibodies and then
counterstained with 4′,6-diamidino-2-phenylindole (DAPI). Scale bar, 50 µm. e The levels of the proteins were measured by the mean ﬂuorescence
intensity. The data are presented as the mean ± SD (n= 5). Two-sided Student’s t-test, *P<0.05, **P<0.005, and ***P<0.001. NS not signiﬁcant
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Therefore, both the numbers and sizes of the tumor
organoids were signiﬁcantly reduced by treatment with
KYA1797K, while no change was observed for treatment
with cetuximab (Fig. 5c). The levels of β-catenin, RAS,
EGFR, and Ki-67 were similarly reduced by KYA1797K
but not by cetuximab (Fig. 5d). Consistent with the results
using the KRAS-mutated CRC cell lines, the combined
effects of KYA1797K and cetuximab on the growth
inhibition were not observed in the tumor organoids
derived from the small intestinal tumor cells of ApcMin/+/
KrasG12DLA2 mice.
To test the potential application of KYA1797K in
humans, we established tumor organoids derived from
CRC patient tissues harboring both APC (truncated form,
Arg216*stop) and KRAS (Gly12Ser) mutations, which
were identiﬁed by whole exome sequencing (Fig. 6a). The
Fig. 5 The effectiveness of KYA1797K on the formation and growth of tumor organoids from the small intestine of ApcMin/+/KrasG12DLA2
mice. The tumor organoids from the small intestine of ApcMin/+/KrasG12DLA2 mice were cultured as described in the materials and methods section.
The tumor organoids were cultured and treated under the indicated conditions for 7 days. a, b The images of the tumor organoids were visualized (a,
scale bar, 200 µm), and the growth of the tumor organoids was measured by a cell titer assay (b). c The numbers (left) and sizes (right) of the tumor
organoids were quantiﬁed. d Immunocytochemical (ICC) analysis of β-catenin, pan-RAS, EGFR, and Ki67 in the tumor organoids treated under the
indicated conditions for 7 days. The tumor organoids were immobilized, immunostained with each antibody, and counterstained with DAPI (d, left
panel). Scale bar, 50 µm. The levels of these proteins were measured by the mean ﬂuorescence intensity (d, right panel). The data are presented as
the mean ± SD (n= 3). Two-sided Student’s t-test, *P<0.05, **P<0.005, and ***P<0.001
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human tumor organoids were well-developed with gland
formation in a time-dependent manner, which recapitu-
lates tumor heterogeneity containing different cell popu-
lations22. However, KYA1797K effectively inhibited gland
formation in tumor organoids (Supplementary Figure S6).
Although cetuximab was not effective, the formation and
growth of tumor organoids were mostly abolished by
KYA1797K (Fig. 6b, c). Therefore, the number and size of
the tumor organoids were signiﬁcantly reduced by treat-
ment with KYA1797K, while no change was shown for
treatment with cetuximab (Fig. 6d). The inhibitory effects
of KYA1797K on the tumor organoids correlated with the
reduction in the β-catenin, pan-RAS, EGFR, and PCNA
levels (Fig. 6e, f). Overall, KYA1797K effectively sup-
pressed the formation and growth of tumor-derived
organoids from CRC patients and overcame the insensi-
tivity to cetuximab attributed to KRAS mutations by
reducing the protein levels via degradation.
Discussion
Cancer development is a dynamic and multistep process
involving multiple genetic changes and molecular
Fig. 6 KYA1797K effectively suppresses the formation and growth of tumor organoids derived from CRC patients having both APC and
KRAS mutations. a The tumor organoids derived from the CRC patient tissue were cultured as described in the materials and methods section and
analyzed by whole exome sequencing to determine the mutational status of the genes of interest, including KRAS and APC. b, c The tumor organoids
were treated under the indicated conditions for 14 days. The tumor organoids were visualized (b, scale bar, 200 µm), and the growth of the tumor
organoids was measured by a cell titer assay (c). d Images of the tumor organoids treated with the indicated conditions for 21 days were captured at
low magniﬁcation (upper panel, scale bar, 1 mm), and high-magniﬁcation images were visualized in the boxed region (inset). The number and size of
the tumor organoids were quantiﬁed (d, lower panel). e ICC analysis of β-catenin, pan-RAS, EGFR, or PCNA in the tumor organoids cultured under the
indicated conditions for 14 days. The tumor organoids were immobilized and then immunostained with antibodies. Scale bar, 50 µm. f The levels of
these proteins were measured by the mean ﬂuorescence intensity. The data are presented as the mean ± SD (n= 3). Two-sided Student’s t-test, ***P
< 0.001
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alterations23,24. In CRC, mutations of genes in the Wnt/β-
catenin and RAS/ERK pathways, such as APC and KRAS,
synergistically promote transformation9,25. Aberrant
activation of the Wnt/β-catenin and RAS/ERK pathways
by the co-stabilization of β-catenin and RAS as well as by
genetic mutations in these pathway components con-
tribute to colorectal tumorigenesis. EGFR is also over-
expressed in human CRC and plays a role in synergistic
tumorigenesis14.
Therefore, the inhibition of both the Wnt/β-catenin and
EGFR-RAS-ERK pathways, especially by reducing the
levels of the proteins elevated in CRC, can be an ideal
approach for the treatment of human CRC. However, a
clinically applicable drug that inhibits both the Wnt/β-
catenin and EGFR-RAS-ERK pathways or even the Wnt/
β-catenin pathway alone is not available. Small molecules
such as KYA1797K reduce the levels of β-catenin, RAS,
and EGFR and are potential drug candidates to resolve the
problem of resistance to EGFR-targeting therapy attrib-
uted to KRAS mutations. The effectiveness of KYA1797K
on the inhibition of cetuximab-resistant KRAS-mutated
CRC cells is shown by both in vitro and in vivo studies
using the mouse xenograft tumor model generated from
CRC cells harboring KRAS mutations. The effectiveness
and potential application of this compound in patients are
demonstrated by the reduction in these proteins and the
suppression of growth in tumor organoids derived from
CRC patient tissues harboring both APC and KRAS
mutations.
The small molecule drugs that reduce the levels of β-
catenin, RAS, and EGFR are highly effective for the
treatment of CRC because of the elevated protein levels
caused by the loss of APC, which is observed in ~90% of
human CRCs. The approach to controlling CRC by the
speciﬁc degradation of the β-catenin and RAS proteins
can be further supported by a recent study suggesting that
the degradation of speciﬁc oncogenic proteins is an ideal
approach for cancer therapy26. Our approach to control-
ling RAS, especially oncogenic mutant KRAS, via its
degradation provides an alternative approach for the
development of a clinically applicable drug targeting the
undruggable RAS27–30. Although β-catenin- and RAS-
destabilizing compounds induced the degradation of
HRAS and NRAS, these could be beneﬁcial for the
treatment of cancer, because the overexpression of WT-
HRAS or -NRAS is known to play roles in the promotion
of MT-KRAS-driven tumorigenesis31. The importance of
the additional KRAS mutations in colorectal tumorigen-
esis with APC mutations is shown by the role of MT
KRAS in the strong secondary activation of Wnt/β-cate-
nin signaling, which involves cancer stem cell activation
by a positive feedback loop via the activation of ERK after
the initial activation of the pathway caused by the loss of
APC25.
In summary, we show that the levels of β-catenin, RAS,
and EGFR are upregulated in a correlated manner by the
loss of APC, and increases in these proteins critically
promote colorectal tumorigenesis. Therefore, small
molecules that degrade both β-catenin and RAS with the
reduction of EGFR transcription can be potential drug
candidates for the treatment of CRC, including CRCs that
are resistant to the EGFR-targeting therapies because of
KRAS mutations.
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